Intrinsic value of Medifast - MED

Previous Close

$215.09

  Intrinsic Value

$2,364

stock screener

  Rating & Target

str. buy

+999%

Previous close

$215.09

 
Intrinsic value

$2,364

 
Up/down potential

+999%

 
Rating

str. buy

We calculate the intrinsic value of MED stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  54.90
  49.91
  45.42
  41.38
  37.74
  34.47
  31.52
  28.87
  26.48
  24.33
  22.40
  20.66
  19.09
  17.68
  16.42
  15.27
  14.25
  13.32
  12.49
  11.74
  11.07
  10.46
  9.91
  9.42
  8.98
  8.58
  8.22
  7.90
  7.61
  7.35
Revenue, $m
  467
  700
  1,018
  1,440
  1,983
  2,666
  3,507
  4,519
  5,716
  7,107
  8,698
  10,496
  12,499
  14,710
  17,125
  19,740
  22,552
  25,557
  28,749
  32,124
  35,679
  39,411
  43,319
  47,400
  51,657
  56,090
  60,703
  65,500
  70,485
  75,666
Variable operating expenses, $m
  243
  364
  530
  749
  1,031
  1,387
  1,824
  2,350
  2,972
  3,695
  4,523
  5,458
  6,500
  7,649
  8,905
  10,265
  11,727
  13,290
  14,949
  16,705
  18,553
  20,494
  22,526
  24,648
  26,862
  29,167
  31,566
  34,060
  36,652
  39,346
Fixed operating expenses, $m
  110
  113
  115
  118
  120
  123
  126
  129
  131
  134
  137
  140
  143
  146
  150
  153
  156
  160
  163
  167
  171
  174
  178
  182
  186
  190
  194
  199
  203
  207
Total operating expenses, $m
  353
  477
  645
  867
  1,151
  1,510
  1,950
  2,479
  3,103
  3,829
  4,660
  5,598
  6,643
  7,795
  9,055
  10,418
  11,883
  13,450
  15,112
  16,872
  18,724
  20,668
  22,704
  24,830
  27,048
  29,357
  31,760
  34,259
  36,855
  39,553
Operating income, $m
  114
  223
  374
  573
  831
  1,157
  1,558
  2,041
  2,612
  3,277
  4,038
  4,898
  5,856
  6,914
  8,070
  9,322
  10,669
  12,108
  13,636
  15,253
  16,955
  18,743
  20,615
  22,570
  24,609
  26,733
  28,943
  31,241
  33,630
  36,112
EBITDA, $m
  120
  232
  387
  592
  857
  1,191
  1,602
  2,099
  2,685
  3,368
  4,149
  5,032
  6,016
  7,103
  8,289
  9,575
  10,958
  12,435
  14,004
  15,664
  17,412
  19,248
  21,169
  23,177
  25,270
  27,451
  29,720
  32,080
  34,532
  37,081
Interest expense (income), $m
  0
  0
  1
  3
  5
  8
  11
  16
  21
  28
  36
  45
  56
  68
  81
  96
  112
  130
  148
  169
  190
  212
  236
  261
  287
  314
  343
  372
  403
  435
  468
Earnings before tax, $m
  114
  222
  371
  568
  824
  1,146
  1,542
  2,019
  2,584
  3,241
  3,993
  4,842
  5,788
  6,833
  7,974
  9,210
  10,539
  11,959
  13,468
  15,063
  16,743
  18,507
  20,354
  22,283
  24,295
  26,391
  28,571
  30,838
  33,195
  35,644
Tax expense, $m
  31
  60
  100
  153
  222
  309
  416
  545
  698
  875
  1,078
  1,307
  1,563
  1,845
  2,153
  2,487
  2,846
  3,229
  3,636
  4,067
  4,521
  4,997
  5,496
  6,016
  6,560
  7,125
  7,714
  8,326
  8,963
  9,624
Net income, $m
  83
  162
  271
  415
  601
  836
  1,125
  1,474
  1,886
  2,366
  2,915
  3,534
  4,226
  4,988
  5,821
  6,723
  7,694
  8,730
  9,831
  10,996
  12,222
  13,510
  14,858
  16,267
  17,735
  19,265
  20,857
  22,512
  24,232
  26,020

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  130
  195
  284
  402
  553
  744
  978
  1,261
  1,594
  1,982
  2,426
  2,928
  3,487
  4,103
  4,777
  5,506
  6,291
  7,129
  8,019
  8,961
  9,952
  10,993
  12,083
  13,222
  14,409
  15,646
  16,933
  18,271
  19,661
  21,106
Adjusted assets (=assets-cash), $m
  130
  195
  284
  402
  553
  744
  978
  1,261
  1,594
  1,982
  2,426
  2,928
  3,487
  4,103
  4,777
  5,506
  6,291
  7,129
  8,019
  8,961
  9,952
  10,993
  12,083
  13,222
  14,409
  15,646
  16,933
  18,271
  19,661
  21,106
Revenue / Adjusted assets
  3.592
  3.590
  3.585
  3.582
  3.586
  3.583
  3.586
  3.584
  3.586
  3.586
  3.585
  3.585
  3.584
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
  3.585
Average production assets, $m
  30
  45
  65
  92
  127
  171
  224
  289
  366
  455
  557
  672
  800
  941
  1,096
  1,263
  1,443
  1,636
  1,840
  2,056
  2,283
  2,522
  2,772
  3,034
  3,306
  3,590
  3,885
  4,192
  4,511
  4,843
Working capital, $m
  -17
  -25
  -37
  -52
  -71
  -96
  -126
  -163
  -206
  -256
  -313
  -378
  -450
  -530
  -616
  -711
  -812
  -920
  -1,035
  -1,156
  -1,284
  -1,419
  -1,559
  -1,706
  -1,860
  -2,019
  -2,185
  -2,358
  -2,537
  -2,724
Total debt, $m
  20
  49
  88
  141
  208
  292
  396
  521
  669
  841
  1,038
  1,260
  1,507
  1,780
  2,079
  2,402
  2,749
  3,121
  3,515
  3,932
  4,372
  4,833
  5,316
  5,820
  6,346
  6,894
  7,464
  8,056
  8,673
  9,313
Total liabilities, $m
  58
  87
  126
  178
  245
  329
  433
  558
  706
  878
  1,075
  1,297
  1,545
  1,818
  2,116
  2,439
  2,787
  3,158
  3,553
  3,970
  4,409
  4,870
  5,353
  5,857
  6,383
  6,931
  7,501
  8,094
  8,710
  9,350
Total equity, $m
  73
  109
  158
  224
  308
  414
  545
  702
  888
  1,104
  1,351
  1,631
  1,942
  2,285
  2,661
  3,067
  3,504
  3,971
  4,467
  4,991
  5,543
  6,123
  6,730
  7,365
  8,026
  8,715
  9,431
  10,177
  10,951
  11,756
Total liabilities and equity, $m
  131
  196
  284
  402
  553
  743
  978
  1,260
  1,594
  1,982
  2,426
  2,928
  3,487
  4,103
  4,777
  5,506
  6,291
  7,129
  8,020
  8,961
  9,952
  10,993
  12,083
  13,222
  14,409
  15,646
  16,932
  18,271
  19,661
  21,106
Debt-to-equity ratio
  0.280
  0.450
  0.560
  0.630
  0.670
  0.710
  0.730
  0.740
  0.750
  0.760
  0.770
  0.770
  0.780
  0.780
  0.780
  0.780
  0.780
  0.790
  0.790
  0.790
  0.790
  0.790
  0.790
  0.790
  0.790
  0.790
  0.790
  0.790
  0.790
  0.790
Adjusted equity ratio
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557
  0.557

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  83
  162
  271
  415
  601
  836
  1,125
  1,474
  1,886
  2,366
  2,915
  3,534
  4,226
  4,988
  5,821
  6,723
  7,694
  8,730
  9,831
  10,996
  12,222
  13,510
  14,858
  16,267
  17,735
  19,265
  20,857
  22,512
  24,232
  26,020
Depreciation, amort., depletion, $m
  6
  9
  13
  18
  25
  34
  45
  58
  73
  91
  111
  134
  160
  188
  219
  253
  289
  327
  368
  411
  457
  504
  554
  607
  661
  718
  777
  838
  902
  969
Funds from operations, $m
  89
  171
  284
  433
  627
  870
  1,170
  1,532
  1,960
  2,457
  3,026
  3,669
  4,386
  5,176
  6,040
  6,976
  7,982
  9,057
  10,199
  11,407
  12,679
  14,015
  15,413
  16,873
  18,397
  19,983
  21,634
  23,350
  25,135
  26,989
Change in working capital, $m
  -6
  -8
  -11
  -15
  -20
  -25
  -30
  -36
  -43
  -50
  -57
  -65
  -72
  -80
  -87
  -94
  -101
  -108
  -115
  -122
  -128
  -134
  -141
  -147
  -153
  -160
  -166
  -173
  -179
  -187
Cash from operations, $m
  95
  180
  295
  449
  646
  895
  1,201
  1,568
  2,003
  2,507
  3,083
  3,733
  4,458
  5,256
  6,127
  7,070
  8,083
  9,165
  10,314
  11,529
  12,807
  14,149
  15,553
  17,020
  18,550
  20,143
  21,800
  23,523
  25,314
  27,175
Maintenance CAPEX, $m
  -4
  -6
  -9
  -13
  -18
  -25
  -34
  -45
  -58
  -73
  -91
  -111
  -134
  -160
  -188
  -219
  -253
  -289
  -327
  -368
  -411
  -457
  -504
  -554
  -607
  -661
  -718
  -777
  -838
  -902
New CAPEX, $m
  -11
  -15
  -20
  -27
  -35
  -44
  -54
  -65
  -77
  -89
  -102
  -115
  -128
  -141
  -155
  -167
  -180
  -192
  -204
  -216
  -228
  -239
  -250
  -261
  -272
  -284
  -295
  -307
  -319
  -332
Cash from investing activities, $m
  -15
  -21
  -29
  -40
  -53
  -69
  -88
  -110
  -135
  -162
  -193
  -226
  -262
  -301
  -343
  -386
  -433
  -481
  -531
  -584
  -639
  -696
  -754
  -815
  -879
  -945
  -1,013
  -1,084
  -1,157
  -1,234
Free cash flow, $m
  80
  159
  266
  409
  593
  826
  1,113
  1,459
  1,868
  2,345
  2,890
  3,507
  4,195
  4,954
  5,784
  6,684
  7,651
  8,684
  9,783
  10,945
  12,168
  13,453
  14,799
  16,205
  17,671
  19,198
  20,787
  22,439
  24,157
  25,941
Issuance/(repayment) of debt, $m
  20
  29
  39
  52
  67
  84
  104
  125
  148
  172
  197
  222
  248
  273
  298
  323
  348
  371
  394
  417
  439
  461
  483
  504
  526
  548
  570
  593
  616
  640
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  20
  29
  39
  52
  67
  84
  104
  125
  148
  172
  197
  222
  248
  273
  298
  323
  348
  371
  394
  417
  439
  461
  483
  504
  526
  548
  570
  593
  616
  640
Total cash flow (excl. dividends), $m
  101
  187
  305
  461
  660
  910
  1,217
  1,584
  2,016
  2,517
  3,087
  3,729
  4,443
  5,228
  6,083
  7,007
  7,998
  9,056
  10,177
  11,362
  12,608
  13,915
  15,282
  16,709
  18,197
  19,746
  21,357
  23,032
  24,773
  26,582
Retained Cash Flow (-), $m
  -26
  -36
  -49
  -65
  -84
  -106
  -131
  -157
  -186
  -216
  -247
  -279
  -311
  -343
  -375
  -406
  -437
  -467
  -496
  -524
  -552
  -580
  -607
  -634
  -661
  -689
  -717
  -745
  -775
  -805
Prev. year cash balance distribution, $m
  62
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  137
  151
  256
  395
  576
  804
  1,086
  1,426
  1,830
  2,300
  2,840
  3,450
  4,131
  4,884
  5,708
  6,600
  7,561
  8,589
  9,681
  10,837
  12,055
  13,335
  14,675
  16,075
  17,535
  19,057
  20,640
  22,286
  23,998
  25,777
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  131
  138
  223
  325
  446
  584
  734
  892
  1,051
  1,206
  1,349
  1,472
  1,571
  1,640
  1,676
  1,677
  1,645
  1,582
  1,491
  1,377
  1,247
  1,106
  962
  819
  682
  556
  443
  345
  262
  194
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Medifast, Inc. produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins. Its business units include Optavia, Medifast Direct, Franchise Medifast Weight Control Centers (MWCC) and Medifast Wholesale. Optavia is a personal coaching division of the Company that consists of Optavia Coaches, who provides coaching and support to clients utilizing the Optavia platform. Medifast Direct is its direct-to-consumer business unit that allows customers to order Medifast products directly through its Website or its in-house call center. The MWCC business unit sells product through franchise and reseller locations, which offers structured programs and a team of professionals to help customers achieve weight-loss and weight-management success at center locations.

FINANCIAL RATIOS  of  Medifast (MED)

Valuation Ratios
P/E Ratio 141.8
Price to Sales 9.3
Price to Book 26.6
Price to Tangible Book
Price to Cash Flow 102.1
Price to Free Cash Flow 116.1
Growth Rates
Sales Growth Rate 0.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate -22.9%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 15.2%
Ret/ On Assets - 3 Yr. Avg. 14.3%
Return On Total Capital 19.5%
Ret/ On T. Cap. - 3 Yr. Avg. 19.2%
Return On Equity 19.5%
Return On Equity - 3 Yr. Avg. 19.2%
Asset Turnover 2.3
Profitability Ratios
Gross Margin 74.9%
Gross Margin - 3 Yr. Avg. 74%
EBITDA Margin 11.6%
EBITDA Margin - 3 Yr. Avg. 13.1%
Operating Margin 9.8%
Oper. Margin - 3 Yr. Avg. 10.3%
Pre-Tax Margin 9.8%
Pre-Tax Margin - 3 Yr. Avg. 10.7%
Net Profit Margin 6.5%
Net Profit Margin - 3 Yr. Avg. 6.1%
Effective Tax Rate 33.3%
Eff/ Tax Rate - 3 Yr. Avg. 33.7%
Payout Ratio 66.7%

MED stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MED stock intrinsic value calculation we used $301.563 million for the last fiscal year's total revenue generated by Medifast. The default revenue input number comes from 0001 income statement of Medifast. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MED stock valuation model: a) initial revenue growth rate of 54.9% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MED is calculated based on our internal credit rating of Medifast, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Medifast.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MED stock the variable cost ratio is equal to 52%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $108 million in the base year in the intrinsic value calculation for MED stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Medifast.

Corporate tax rate of 27% is the nominal tax rate for Medifast. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MED stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MED are equal to 6.4%.

Life of production assets of 4.6 years is the average useful life of capital assets used in Medifast operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MED is equal to -3.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $108.581 million for Medifast - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 11.951 million for Medifast is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Medifast at the current share price and the inputted number of shares is $2.6 billion.

RELATED COMPANIES Price Int.Val. Rating
NTRI Nutrisystem 37.50 29.59  sell
WTW Weight Watcher 69.76 29.17  str.sell
CAG Conagra Brands 37.45 53.64  buy

COMPANY NEWS

▶ Buy Medifast Stock as It Continues to Soar   [Sep-18-18 12:22PM  InvestorPlace]
▶ Medifast, Inc. Announces Quarterly Dividend   [Sep-06-18 04:30PM  PR Newswire]
▶ Anatomy of Success: Medifast Inc. (MED)   [Aug-27-18 01:48PM  Zacks]
▶ The top Baltimore-area performers during the stock market's longest bull run   [Aug-22-18 03:03PM  American City Business Journals]
▶ Buy These 5 Low-Beta Stocks to Brave Market Volatility   [Aug-20-18 05:40PM  InvestorPlace]
▶ Medifast Stock Is Still Worth Pouring Into   [12:06PM  InvestorPlace]
▶ New Strong Buy Stocks for August 8th   [Aug-08-18 11:22AM  Zacks]
▶ Medifast shares are up almost 200 percent this year. Here's a deeper look why.   [Aug-06-18 12:32PM  American City Business Journals]
▶ Stock Indexes Mixed In Muted Reaction To Jobs Report   [03:04PM  Investor's Business Daily]
▶ Medifast: 2Q Earnings Snapshot   [06:36PM  Associated Press]
▶ Medifast shares surpass $200 as profit, sales again beat expectations   [04:47PM  American City Business Journals]
▶ Medifast, Inc. to Host Earnings Call   [02:30PM  ACCESSWIRE]
▶ Holding on: Local companies are navigating an unpredictable stock market   [Jul-13-18 05:00AM  American City Business Journals]
▶ Medifast Is Overlooked and Underappreciated   [Jul-11-18 12:19PM  InvestorPlace]
▶ Medifast stock, up 130 percent this year, among biggest gainers in U.S.   [Jun-29-18 02:40PM  American City Business Journals]
▶ Is Medifast Incs (NYSE:MED) Liquidity Good Enough?   [Jun-22-18 12:27PM  Simply Wall St.]
▶ Reasons Why I Like Medifast Inc (NYSE:MED)   [Jun-20-18 11:09AM  Simply Wall St.]
▶ 6 Defensive Stocks to Buy as Trade Tensions Flare Up   [Jun-18-18 01:55PM  InvestorPlace]
▶ Medifast, Inc. Announces Quarterly Dividend   [Jun-14-18 04:30PM  PR Newswire]
▶ Leverage the Price Momentum of These 4 Stocks   [Jun-11-18 03:29PM  Zacks]
▶ 3 Food Stocks to Please Investors' Palate   [Jun-06-18 09:31AM  Zacks]
▶ BRF S.A. (BRFS) Surges: Stock Moves 8.3% Higher   [Jun-04-18 08:49AM  Zacks]
▶ When Should You Buy Medifast Inc (NYSE:MED)?   [Jun-01-18 01:38PM  Simply Wall St.]
▶ Here's how much more CEOs at Baltimore public companies make than their employees   [May-05-18 08:43AM  American City Business Journals]
▶ Medifast: 1Q Earnings Snapshot   [May-03-18 06:27PM  Associated Press]
▶ Medifast shares surge after reporting profits doubled in 1Q   [04:51PM  American City Business Journals]
▶ Medifast CEO Daniel Chard gets a big bonus for boosting sales   [May-02-18 01:56PM  American City Business Journals]
▶ Gatheredtable software licensed by Medifast   [Apr-23-18 10:30AM  PR Newswire]
▶ Can The Uptrend Continue for Medifast (MED)?   [Mar-23-18 11:03AM  Zacks]
▶ Medifast, Inc. Announces Quarterly Dividend   [Mar-15-18 04:15PM  PR Newswire]
▶ 3 Stocks Move Wednesday   [10:01AM  GuruFocus.com]
▶ Medifast profit up 78% in 4Q; activist investor steps down from board   [Mar-06-18 05:32PM  American City Business Journals]
▶ Medifast to begin selling in Hong Kong and Singapore next year   [02:36PM  American City Business Journals]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.